Geisinger Commonwealth’s Doylestown campus celebrates FDA approval of TRULANCE Monday, March 13, 2017 Geisinger Commonwealth School of Medicine’s Doylestown campus recently celebrated the FDA approval of TRULANCE, a drug developed by Kunwar Shailubhai, PhD, MBA, executive vice president and chief scientific officer of Synergy Pharmaceuticals. Dr. Shailubhai is also a faculty member at the Baruch S. Blumberg Institute (BSBI) and at Geisinger Commonwealth. The celebration was significant for Geisinger Commonwealth master of biomedical science students because they have the opportunity to work alongside of scientists like Dr. Shailubhai and other life sciences entrepreneurs located in the Pennsylvania Biotechnology Center in Doylestown, which is also the home of BSBI and a Geisinger Commonwealth campus. Dr. Shailubhai’s TRULANCE is the first drug to be discovered and developed at the Doylestown campus and among the first four new drugs to receive FDA approval in 2017. Seen celebrating TRULANCE’s FDA approval, from left, are Gary Jacob, PhD, chair of the board and chief executive officer,-Synergy Pharmaceuticals; Ela Saxena; Nicolas Maffetone, Geisinger Commonwealth School of Medicine (Geisinger Commonwealth) master of biomedical science (MBS) student; Dr. Kunwar Shailubhai, co-founder and chief scientific officer, Synergy Pharmaceuticals; Sierra McCloud, Geisinger Commonwealth MBS student; Tonia Sofoluke, Geisinger Commonwealth MBS student; Josephine Sinamano, Geisinger Commonwealth MBS student; and John Kulp, PhD, regional assistant dean, Geisinger Commonwealth and director of academic affairs, Baruch S. Blumberg Institute (BSBI). TCMC Media Contact: Elizabeth ZygmuntDirector of Media and Public Relations Office: 570-504-9687On Call: 570-687-9703 Geisinger Commonwealth School of Medicine is committed to non-discrimination in all employment and educational opportunities.